Publication Name	World Journal of Gastroenterology
Manuscript ID	21355
Country	Greece

Received	2015-07-08 15:26
Peer-Review Started	2015-07-08 17:51
To Make the First Decision	2015-07-20 14:43
Return for Revision	2015-07-24 16:39
Revised	2015-07-24 18:26
Second Decision	2015-10-10 18:48
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-10-13 18:20
Articles in Press	2015-10-13 18:20
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-11-05 05:34
Typeset the Manuscript	2015-11-25 11:48
Publish the Manuscript Online	2015-12-15 12:22

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease
Manuscript Source	Invited Manuscript
All Author List	Ioannis Androulakis, Christos Zavos, Panagiotis Christopoulos, George Mastorakos and Maria Gazouli
Funding Agency and Grant Number
Corresponding Author	Maria Gazouli, Assist Professor, Department of Basic Biological Sciences, Laboratory of Biology, School of Medicine, University of Athens, Michalakopoulou 176, 11527 Athens, Greece. mgazouli@med.uoa.gr
Key Words	Anti-tumor necrosis factor; Pregnancy; Adverse effects; Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease
Core Tip	Modern inflammatory bowel disease treatment includes biological therapy, such as anti-tumor necrosis factor (TNF) agents. There are concerns over the use of anti-TNF agents during pregnancy, although the data available to date are limited. No significant increases in the adverse outcomes of pregnancy have been reported in women who continued their treatment from conception to the first trimester of pregnancy. Decision making in this case dictates that the mother’s benefits of maintaining relapse of the disease through continuation of anti-TNFs exceeds the potential risks of fetal exposure.
Publish Date	2015-12-15 12:22
Citation	Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol 2015; 21(47): 13205-13211
URL	http://www.wjgnet.com/1007-9327/full/v21/i47/13205.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i47.13205

Full Article (PDF)	WJG-21-13205.pdf
Full Article (Word)	WJG-21-13205.doc
Manuscript File	21355-Review.doc
Answering Reviewers	21355-Answering reviewers.pdf
Audio Core Tip	21355-Audio core tip.wav
Conflict-of-Interest Disclosure Form	21355-Conflict-of-interest statement.pdf
Copyright License Agreement	21355-Copyright assignment.pdf
Peer-review Report	21355-Peer-review(s).pdf
Scientific Misconduct Check	21355-Scientific misconduct check.pdf
Scientific Editor Work List	21355-Scientific editor work list.pdf